Liraglutide Market Report 2025

This Liraglutide market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The liraglutide market size has grown strongly in recent years. It will grow from $6.38 billion in 2024 to $6.95 billion in 2025 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to the increasing number of people diagnosed with type 2 diabetes, growing obesity rates, extensive clinical trials, growing awareness of diabetes complications, and rising innovations in drug delivery systems.

The liraglutide market size is expected to see strong growth in the next few years. It will grow to $9.66 billion in 2029 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to increasing insurance and reimbursement policies, healthcare infrastructure development, increasing awareness and educational initiatives, a growing aging population, and the increasing prevalence of diabetes. Major trends in the forecast period include the use of artificial intelligence and machine learning, demand for wearable technology, continuous glucose monitoring integration, biotechnology advancements, and the development of digital health platforms.

The growing diabetic population is anticipated to drive the expansion of the liraglutide market in the coming years. Diabetes is a long-term condition in which the body struggles to regulate blood sugar levels effectively, either due to inadequate insulin production or ineffective insulin utilization. The prevalence of diabetes is rising due to factors such as sedentary lifestyles, poor dietary habits, and increasing obesity rates globally. Diabetes medications like liraglutide aid in managing type 2 diabetes by mimicking the effects of the hormone GLP-1, which enhances insulin release, reduces blood sugar levels, and supports weight loss. For example, in March 2024, a report by the Government of the United Kingdom indicated that in March 2023, the proportion of individuals with type 1 diabetes in England receiving all 8 care processes at participating GP practices in the NDA rose to 43.8%, up from 35.2% the previous year. Therefore, the rising diabetic population is driving the growth of the liraglutide market.

Leading companies in the liraglutide market are creating innovative products, such as generic GLP-1, to broaden treatment options and meet the demand for more affordable alternatives. Generic GLP-1 refers to versions of GLP-1 receptor agonists produced after the original branded medications' patent protection has expired, providing cost-effective options for treating conditions such as type 2 diabetes and obesity. For example, in June 2024, Teva Pharmaceutical Industries Ltd., a pharmaceutical company based in Israel, launched the first generic GLP-1 similar to Victoza in the U.S. market, addressing the growing need for these therapies. Liraglutide injections are prescribed to improve blood sugar management in adults and children aged 10 and older with type 2 diabetes and to reduce the risk of cardiovascular events in adults with type 2 diabetes and existing cardiovascular conditions.

In October 2023, Biocon Limited, a biopharmaceutical company based in India, entered into a partnership with Juno Pharmaceuticals to commercialize its vertically integrated, complex formulation, Liraglutide. According to the terms of the agreement, Biocon will handle the regulatory approval process for Liraglutide and will subsequently manage the manufacturing and supply of the product in the Canadian market. Juno Pharmaceuticals, a Canada-based pharmaceutical company, specializes in introducing complex and high-value generic and biosimilar products to the market.

Major companies operating in the liraglutide market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis International AG, Takeda Pharmaceutical Company Limited, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Cipla Limited, Dr. Reddy's Laboratories Ltd., Biocon Limited, Hanmi Pharmaceutical Co. Ltd., Intarcia Therapeutics Inc., Adocia SA.

North America was the largest region in the liraglutide market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the liraglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the liraglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Liraglutide is a GLP-1 receptor agonist utilized for managing type 2 diabetes and obesity. It lowers blood sugar levels and encourages weight loss by imitating the incretin hormone GLP-1. Given through subcutaneous injection, it boosts insulin secretion and curbs appetite. Liraglutide is available under the brand names Victoza for diabetes and Saxenda for obesity.

The primary brands of liraglutide are Victoza and Saxenda. Victoza is a brand name for liraglutide, a medication prescribed for type 2 diabetes. It can be obtained from hospital pharmacies, retail pharmacies, drug stores, and online pharmacies, and is used for managing diabetes and weight. It is utilized by different end-users, such as hospitals, clinics, and home care settings.

The liraglutide market research report is one of a series of new reports that provides liraglutide market statistics, including liraglutide industry global market size, regional shares, competitors with a liraglutide market share, detailed liraglutide market segments, market trends and opportunities, and any further data you may need to thrive in the liraglutide industry. This liraglutide market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The liraglutide market consists of sales of insulin products, weight management supplements, nutritional supplements, and related products. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.